{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T06:29:27Z","timestamp":1766557767061,"version":"3.41.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>We have now about 20\u200ayears of experience with the treatment of axial spondyloarthritis with biologics, which raises the question what we can learn from past experience, and which open questions should be addressed in future investigations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Many studies have shown that axSpA patients \u2013 both patients in their nonradiological and radiological stage \u2013 respond similarly well to biologic treatment and these patients should be seen as having the same disease at different stages. AxSpA respond best to TNF-blocker \u2013 and probably also to other biologics \u2013 if the disease duration is short and if objective parameters of inflammation, such as C-reactive protein or MRI are positive. Primary aim of treatment is to reach and maintain clinical remission. Once remission is achieved, it can be maintained by continuing treatment, and in a proportion of yet not well defined patients the drug dose can be reduced without inducing a flare. The recent demonstration of a good efficacy, in addition to TNF blockers, also of IL-17 inhibitors and JAK-inhibitors in axSpA patients raises the question how to select the best patients for the best treatment. Radiographic progression can best be stopped by effectively suppressing inflammation, whether different drugs have here a different effect has still to be defined. More sensitive measurements of radiographic progression are urgently needed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Reaching and maintaining clinical remission and preventing structural bony damage is the primary treatment target in patients with axSpA. How to reach this aim best has to be further explored in the future.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000804","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T14:00:07Z","timestamp":1620828007000},"page":"363-369","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Twenty years of clinical trials in axial spondyloarthritis: what can we learn for the future?"],"prefix":"10.1097","volume":"33","author":[{"given":"Joachim","family":"Sieper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11926-017-0681-5","article-title":"Mechanism of new bone formation in axial spondyloarthritis","volume":"19","author":"Poddubnyy","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.40866","article-title":"A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with nonradiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with nonradiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nrrheum.2016.42","article-title":"New evidence on the management of spondyloarthritis","volume":"12","author":"Sieper","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/annrheumdis-2012-202389","article-title":"Similar response rates in patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis after 1\u200ayear of treatment with etanercept: results from the ESTHER trial","volume":"72","author":"Song","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landewe","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","article-title":"Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction","volume":"79","author":"Landewe","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ard.2007.073098","article-title":"MRI in predicting a major clinical response to antitumour necrosis factor treatment in ankylosing spondylitis","volume":"67","author":"Rudwaleit","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","article-title":"Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis","volume":"60","author":"Barkham","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1186\/ar4464","article-title":"Good correlation between changes in objective and subjective signs of inflammation in short- but not long-diseased patients with axial spondyloarthritis treated with tumor necrosis factor-blockers","volume":"16","author":"Weiss","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","article-title":"Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with nonradiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study","volume":"392","author":"Landewe","year":"2018","journal-title":"Lancet"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"e000917","DOI":"10.1136\/rmdopen-2019-000917","article-title":"Predictors of remission in patients with nonradiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study","volume":"5","author":"Sieper","year":"2019","journal-title":"RMD Open"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1002\/art.38613","article-title":"Effectiveness of tumor necrosis factor alpha blockers in early axial spondyloarthritis: data from the DESIR cohort","volume":"66","author":"Molto","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/annrheumdis-2011-201010","article-title":"Frequency and duration of drug-free remission after 1\u200ayear of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2\u200ayear data of the ESTHER trial","volume":"71","author":"Song","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/annrheumdis-2013-203460","article-title":"Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","article-title":"Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study","volume":"73","author":"Deodhar","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying antirheumatic drugs (COAST-V): 16\u200aweek results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/rheumatology\/kex361","article-title":"What is the best treatment target in axial spondyloarthritis: tumour necrosis factor alpha, interleukin 17, or both?","volume":"57","author":"Poddubnyy","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/annrheumdis-2017-211989","article-title":"Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort","volume":"77","author":"de Koning","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3899\/jrheum.160594","article-title":"Physical function and spinal mobility remain stable despite radiographic spinal progression in patients with ankylosing spondylitis treated with TNF-alpha inhibitors for up to 10 years","volume":"43","author":"Poddubnyy","year":"2016","journal-title":"J Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:18:57Z","timestamp":1748294337000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000804","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"type":"print","value":"1040-8711"},{"type":"electronic","value":"1531-6963"}],"subject":[],"published":{"date-parts":[[2021,5,11]]}}}